ACON Exits iiMED Medical Solutions and Completes Full Exit of its IIMAK Investment

ACON Investments, L.L.C. and its affiliates (“ACON”) announced today that it has completed the sale of its equity interests in iiMED Medical Solutions, L.L.C. (“iiMED” or the “Company“) to TEAM Technologies, Inc. (“TEAM”). TEAM is backed by affiliates of Clearlake Capital Group, L.P.  Terms of the transaction were not disclosed.

Headquartered in Amherst, New York, with manufacturing facilities in Mexico, iiMED is a nearshore specialty manufacturer of Class I and Class II consumable medical devices. The Company’s target end-markets include patient monitoring, wound care, and compression therapy devices with core capabilities of flame lamination, converting, sewing and clean room assembly.

During ACON’s three-year ownership, iiMED had strong performance and grew approximately 25% year-over-year. “This investment is a great example of ACON’s deep industry expertise and nimbleness, which allowed us to unlock value through a unique carve out strategy,” said Anjali Jolly, a Partner of ACON. “This exit validates our thesis of the strong tailwinds in the medical specialty manufacturing space that are increasingly driven by OEM interest in nearshore partners,” added John Roush, advisor to ACON and Chairman of iiMED’s Board.

Together with ACON’s sale of IIMAK’s industrial business on September 30, 2021, ACON has successfully exited its investment entirely.

“ACON’s experience and resources were instrumental in fueling iiMED’s accelerated organic growth over the past three years. Our partnership with ACON was highly collaborative and critical to our success. We are excited to partner with TEAM to further build upon our exciting growth trajectory,” said Bill Flaherty, CEO of iiMED.

TEAM is a growth-oriented North American engineering solutions and specialty manufacturer serving healthcare end-markets.  “We are excited to welcome iiMED to the TEAM family as we continue expanding our specialty healthcare manufacturing capabilities,” said Marshall White, President and CEO of TEAM.  “The acquisition of iiMED enables us to continue to scale our platform and enhance our portfolio of solutions to serve our OEM customers.  We look forward to working with iiMED’s talented employees to grow our combined businesses.”

Hot this week

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.